Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb/III randomized double-blind active-controlled study of XNW3009 in patients with gout
CTR20222360Phase 3Active
- Sponsor
- Sinovent
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xininurad in gout, sponsored by Sinovent. Started Oct 2022; status: active.
02
Drugs
xininurad
03
Conditions
gout
Beyond the preview
Go deeper on CTR20222360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222360.